The clinical study of new potential VELDONA-based animal drug is poised to expand VELDONA's market.
First Batch of 300,000 Units to be Fully Delivered in October
Ainos, Inc. (NASDAQ: AIMD) is engaged as a diversified medical technology company, which is focused on developing innovative point-of-care testing
/PRNewswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care...
/PRNewswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care...
/PRNewswire/ -- Ainos, Inc. (OTC PINK: AIMD) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care...
SAN DIEGO, CA / ACCESSWIRE / June 21, 2022 / Ainos, Inc. (OTC PINK:AIMD) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon...
SAN DIEGO, CA / ACCESSWIRE / December 7, 2021 / Ainos, Inc. ("we", "our", or the "company"), (OTC PINK:AIMD), a diversified healthcare company engaged in the discovery and development of pharmaceutical,...
SAN DIEGO, CA / ACCESSWIRE / November 3, 2021 / Ainos, Inc. ("we", "our", or the "company"), (OTC PINK:AIMD), announced today that the company has recently achieved early stage milestones in its mRNA vaccine...
SAN DIEGO, CA / ACCESSWIRE / August 16, 2021 / Ainos, Inc. ("we", "our", or the "Company"), (OTC PINK:AIMD), elected Ms. Hui-Lan (Celia) Wu as its new Chief Financial Officer ("CFO"). Ms. Wu succeeds Mr....